shr-9839
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2023 (NCT05836948)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07229638 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06754930 | Phase 1/Phase 2 (Phase 2) | Feb 18, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06703177 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06474455 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2024 | Hengrui Therapeutics, Inc. |
| NCT05836948 | Phase 1 | May 1, 2023 | Hengrui Therapeutics, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 3 | 3 | 1 | 2024 |
| Hengrui Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2023 |
2 organizations
Page 1 / 1